---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-23-000020"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2023-02-09T23:59:59+00:00"
generated_at: "2026-06-19T20:14:12.152912+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nurix reports FY2022 net loss $180.4M, cash $373M; NX-2127 shows clinical benefit in CLL

## Summary
- Net loss for FY ended Nov 30, 2022: $180.4M ($3.71/shr) vs $117.2M ($2.73/shr) in FY2021; R&D expense $184.5M.
- Cash and marketable securities at $373.0M on Nov 30, 2022, down from $432.9M at Nov 30, 2021; collaboration revenue $38.6M.
- NX-2127 BTK degrader achieved clinical responses in heavily pretreated CLL patients with BTK inhibitor resistance mutations.
- Initial PK/PD data for NX-5948 showed rapid, sustained BTK degradation; FDA clearance for US trial expansion received Dec 2022.
- Nurix expects to present additional clinical data for NX-2127, NX-5948, and NX-1607 in 2H 2023; partnered 10 discovery programs.

## SEC filing metadata
- accession: 0001549595-23-000020
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2023-02-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000020/0001549595-23-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000020/nrix-20230209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-23-000020
- JSON: https://secwatch.observer/filing/0001549595-23-000020.json
- Plain text: https://secwatch.observer/filing/0001549595-23-000020.txt

## Key facts
- Earnings Releases
  Nurix Therapeutics, Inc. reported financial results for the fourth quarter and fiscal year ended November 30, 2022.
  - Period: the fourth quarter and fiscal year ended November 30, 2022
  - Result: reported results
  source text: On February 9, 2023, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal year ended November 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000020/0001549595-23-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.